There are 1076 resources available
648P - The efficacy of ICIs plus platinum-based chemotherapy for patients with advanced NSCLC and ECOG PS 2 (WJOG18424L): A propensity score-matched study
Presenter: Shunichi Kataoka
Session: Poster Display session
Resources:
Abstract
649P - An oral, chemo-free regimen (osimertinib plus anlotinib) as first-line treatment for EGFR-mutated advanced NSCLC (AUTOMAN): Safety and survival outcome
Presenter: Baohui Han
Session: Poster Display session
Resources:
Abstract
650P - Impact of different lymph node status on prognosis in patients with non-small cell lung cancer after neoadjuvant chemoimmunotherapy: A multicenter retrospective cohort study
Presenter: Ran Ma
Session: Poster Display session
Resources:
Abstract
651P - Efficacy and safety outcomes of Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study): Long-term follow-up analysis
Presenter: Yongfeng Yu
Session: Poster Display session
Resources:
Abstract
652P - 3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer
Presenter: Claire Verschraegen
Session: Poster Display session
Resources:
Abstract
653P - Baseline and 3 weeks on-treatment plasma EGFR mutation (EGFRm) dynamics in patients with EGFR mutant advanced NSCLC treated with first-line osimertinib: A prospective, multi-center, real-world analysis
Presenter: Jie Wang
Session: Poster Display session
Resources:
Abstract
654P - Efficacy and safety of first-line ipilimumab and nivolumab treatment in elderly patients with non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster Display session
Resources:
Abstract
655P - De novo MET amplification in EGFR-mutant non-small cell lung cancer
Presenter: David Lee
Session: Poster Display session
Resources:
Abstract
656P - Real-World (RW) frontline (1L) treatments (Txs) in patients (Pts) with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EFGR) exon 20 insertions (exon20ins) and adjusted comparisons versus PAPILLON study
Presenter: Ziming Li
Session: Poster Display session
Resources:
Abstract
657P - Landscape of KRAS mutations in non-small cell lung cancer (NSCLC) patients from Asia and Middle East (AME) using circulating tumor DNA (ctDNA)
Presenter: Amit Rauthan
Session: Poster Display session
Resources:
Abstract